CN1183935C - Notoginseng and fermented red rice composition for preventing and treating cardiac and cerebral vascular diseases - Google Patents
Notoginseng and fermented red rice composition for preventing and treating cardiac and cerebral vascular diseases Download PDFInfo
- Publication number
- CN1183935C CN1183935C CNB021137978A CN02113797A CN1183935C CN 1183935 C CN1183935 C CN 1183935C CN B021137978 A CNB021137978 A CN B021137978A CN 02113797 A CN02113797 A CN 02113797A CN 1183935 C CN1183935 C CN 1183935C
- Authority
- CN
- China
- Prior art keywords
- monacus
- monascus
- notoginseng
- composition
- red rice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 235000003143 Panax notoginseng Nutrition 0.000 title claims abstract description 38
- 241000180649 Panax notoginseng Species 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 235000007189 Oryza longistaminata Nutrition 0.000 title abstract description 10
- 240000007594 Oryza sativa Species 0.000 title abstract description 10
- 235000007164 Oryza sativa Nutrition 0.000 title abstract description 10
- 230000000747 cardiac effect Effects 0.000 title description 2
- 230000002490 cerebral effect Effects 0.000 title 1
- 208000019553 vascular disease Diseases 0.000 title 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 20
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 19
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 19
- 239000000843 powder Substances 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 235000013373 food additive Nutrition 0.000 claims abstract description 4
- 239000002778 food additive Substances 0.000 claims abstract description 4
- 244000113306 Monascus purpureus Species 0.000 claims description 29
- 235000002322 Monascus purpureus Nutrition 0.000 claims description 29
- 229940057059 monascus purpureus Drugs 0.000 claims description 29
- 241000228347 Monascus <ascomycete fungus> Species 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000004040 coloring Methods 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 6
- 235000013402 health food Nutrition 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 2
- 101001018064 Homo sapiens Lysosomal-trafficking regulator Proteins 0.000 claims description 2
- 102100033472 Lysosomal-trafficking regulator Human genes 0.000 claims description 2
- 244000038561 Modiola caroliniana Species 0.000 claims description 2
- 235000010703 Modiola caroliniana Nutrition 0.000 claims description 2
- 241000235395 Mucor Species 0.000 claims description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims description 2
- 239000000284 extract Substances 0.000 abstract description 12
- 235000013305 food Nutrition 0.000 abstract description 3
- 239000002775 capsule Substances 0.000 abstract description 2
- 239000008187 granular material Substances 0.000 abstract description 2
- 239000007902 hard capsule Substances 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 239000007901 soft capsule Substances 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 description 33
- 239000008280 blood Substances 0.000 description 33
- 230000000694 effects Effects 0.000 description 15
- 238000012546 transfer Methods 0.000 description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 11
- 229960004844 lovastatin Drugs 0.000 description 11
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 10
- 201000001320 Atherosclerosis Diseases 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 230000036772 blood pressure Effects 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000001631 hypertensive effect Effects 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 230000000055 hyoplipidemic effect Effects 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 239000008802 xuezhikang Substances 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229940097420 Diuretic Drugs 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 230000001610 euglycemic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229930185723 monacolin Natural products 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000012666 negative regulation of transcription by glucose Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a composition of notoginseng and red rice, which is used for preventing or treating cardiovascular and cerebrovascular diseases. The composition can effectively and safely prevent or treat cardiovascular and cerebrovascular diseases. In the present invention, notoginseng and red rice are used as raw materials, and are mixed with the ratio of dry notoginseng to dry red rice: 10 to 90 wt%: 90 to 10 w%; notoginseng, and the extract, the effective fractions and the effective components of the notoginseng all can be used as raw materials; red rice, and the extract, the effective fractions and the effective components of the red rice all can be used as raw materials; the composition of the notoginseng or the extract of the notoginseng, and the red rice or the extract of the red rice utilizes the obvious synergistic effects of all the components rather than simple addition to prepare the composition. The composition can be made into preparations which can be medically accepted, such as tablets, capsules (soft capsules or hard capsules), granules, medicinal powder, etc. The composition can be applied to health care food or food additives.
Description
Affiliated field: medicine of the present invention and field of food are that the Radix Notoginseng and the Monas cuspurpureus Went of a kind of prevention or treatment cardiovascular and cerebrovascular disease is the compositions that raw material is formed.
Background technology; In recent years, along with growth in the living standard and social population's aging, cardiovascular and cerebrovascular disease, as coronary heart disease, acute cerebrovascular disease, peripheral blood vessel etc., sickness rate has the trend that raises year by year, serious harm human life health.
Cardiovascular and cerebrovascular disease is because of due to the atherosclerosis to a great extent, and atherosclerosis is the chronic disease due to the risk factor more than, and principal risk factor has: dyslipidemia, smoking, hypertension and diabetes etc.Therefore, from the treatment of starting with of several respects such as blood lipid regulation, blood pressure regulation, blood sugar regulation, the control of cardiovascular and cerebrovascular disease had the important clinical meaning.
Treating hyperlipidemia in the market mainly contains: Statins, the special class of shellfish, bile acid chelating agent and nicotinic acid class.Treat hypertensive medicine the most frequently used be: diuretic, beta-blocker, calcium antagonist, angiotensin converting enzyme inhibitor and α receptor blocking agent.The medicine of treatment diabetes has: biguanides, Alpha-glucosidase inhibitor and euglycemic agent---thiazolidinedione etc.With these medicines the control of cardiovascular and cerebrovascular disease has been obtained certain effect clinically, but it is remarkable to take side effect for a long time, and patient's body and mind is caused harmful effect.
Therefore, according to the characteristics that cardiovascular and cerebrovascular disease need be taken medicine for a long time, should adopt effectively and the little natural product of toxic and side effects is advisable.
Chinese patent application, application number: 00135783.2, name is called " a kind of natural composition and application thereof that prevents and treats cardiovascular and cerebrovascular disease ", and its compositions also relates to Radix Notoginseng and mycetogenetic hypolipidemic activity composition---lovastatin.Yet the Monas cuspurpureus Went effect for reducing blood fat is the synergistic result of multiple composition, and lovastatin is one of blood fat reducing effective ingredient in the Monas cuspurpureus Went, and this is the difference of patent of the present invention and foregoing invention patent.
Summary of the invention: at the deficiency of present control cardiovascular and cerebrovascular diseases medicament, the object of the present invention is to provide Radix Notoginseng, the fermented red rice composition of a kind of prevention or treatment cardiovascular and cerebrovascular disease, prevention that it can be effective, safe or treatment cardiovascular and cerebrovascular disease.
The present invention also aims to pass through medicine efficacy screening, prescription raw material and extract, effective site or effective ingredient are carried out different proportion relation researchs, find out and a kind ofly act on body, thereby can prevent and treat the proportion relation of the optimum feed stock of cardiovascular and cerebrovascular disease comprehensively by number of ways.
The present invention also aims on above research basis, develop a series of medicines that are easy to carry and take, health food or food additive.
Purpose of the present invention realizes by following measure:
With Radix Notoginseng and Monas cuspurpureus Went is raw material, by the dry matter weight Radix Notoginseng: Monas cuspurpureus Went=(10%～90%): the mixed of (90%～10%).
The fungus of above-mentioned generation Monas cuspurpureus Went can be monascus (Monacus anka), Mauve aspergillar (MonacusPurpureus), monascus (Monacus albidus) turns white, Bark monascus (Monacus barkeri), smoky gray monascus (Monacus fulignosus), red monascus (Monacus rubervam), rust monascus (Monacus rubiginosus), in monascus (Monacus serorubescens) and the Mucor shape monascus (Monacus mucoroides) any reddens.
Above-mentioned Radix Notoginseng (Panax notoginseng) and extract, effective site and effective ingredient all can be used as raw material; Monas cuspurpureus Went and extract thereof, effective site and effective ingredient all can be used as raw material.
Said composition can be an acceptable preparation medically, as, tablet, capsule (soft capsule or hard capsule), granule, powder etc.Said composition can be applicable to health food or food additive.
The effect of below introducing Radix Notoginseng in the prescription, Monas cuspurpureus Went with the relevant drug efficacy study of control cardiovascular and cerebrovascular disease:
(1), Radix Notoginseng
Radix Notoginseng sweet in the mouth warm in nature, little hardship are gone into liver, stomach warp, and eliminating stasis to stop pain is arranged, and the effect of subduing swelling and relieving pain studies have shown that the extensive of its drug effect, and it is better and toxicity is less that Radix Notoginseng is used for cardio-cerebrovascular aspect effect.
1, blood pressure lowering
The intravenous injection Radix Notoginseng total arasaponins can make the aortic pressure of Canis familiaris L. reduce, and the diastolic pressure fall is bigger than systolic pressure, and its underpressure and dosage are proportionate.The Radix Notoginseng total arasaponins blood pressure lowering mainly is because of direct blood vessel dilating, also may be relevant with the inhibition cardiac contractility.
2, blood fat reducing
Radix Notoginseng total arasaponins is influential to the content of serum lipids, and administration group high density lipoprotein (HDL-C), HDL-C/TC value are all obviously greater than matched group, but serum triglycerides (TC) and T-CHOL (TG) content and matched group comparing difference are not obvious.
3, blood sugar regulation
Radix Notoginseng extract has dual regulation to blood glucose, and the mice fasting glucose that can slightly raise also can have hypoglycemic activity preferably to alloxan induced mice hyperglycemia.
Radix Notoginseng total arasaponins has the rising blood glucose effect of significant collaborative glucagon.Panax Notoginseng saponin R g
1The blood glucose increasing effect of tangible antagonism glucagon is arranged, can also reduce the alloxan diabetes mouse blood sugar, and dose-effect relationship is obvious.
4, atherosclerosis
Radix Notoginseng total arasaponins is formed with obvious inhibitory action to experimental atherosclerosis rabbit aorta inner membrance speckle, its mechanism of action may with the Radix Notoginseng total arasaponins arterial wall prostaglandin I that raises
2(PGI
2), reduce the plain A of platelet thrombus
2(TXA
2) content, thereby correct modeling rabbit PGI
2-TXA
2Between unbalance, it is relevant to stablize blood vessel internal ring border.
(2) Monas cuspurpureus Went
Monas cuspurpureus Went sweet in the mouth warm in nature is gone into liver, spleen, large intestine channel, and blood circulation promoting and blood stasis dispelling is arranged, and the effect of strengthening the spleen to promote digestion for China's traditional zymotic product, is mainly used in the food and medicine aspect.From 1979, extraction separation obtained the synthetic rate-limiting enzyme 3-hydroxyl of cholesterol-3-glutaryl CoA reductase inhibitor from Monas cuspurpureus Went---and since the Monacolin-K (being lovastatin), just increasingly extensive and deep to the research of Monas cuspurpureus Went medical value both at home and abroad.
1, blood fat reducing
Hongqu powder (red colouring agent) has prevention and therapeutic effect preferably to hyperlipemia, and anti-atherogenic speckle formation effect is preferably arranged, and dosage becomes positive correlation with drug effect.
The ethanol extraction of Monas cuspurpureus Went has the effect that reduces hyperlipemia Carnis Coturnicis japonicae serum total cholesterol (TC), triglyceride (TG), low density lipoprotein, LDL (LDL-C), and hypolipidemic activity and lovastatin content are proportionate.Research finds that also when as long as the blood concentration of Monacolin constituents reaches 0.001～0.005ug/ml, cholesterol is synthetic will to be suppressed.
In addition, research also finds in the Monas cuspurpureus Went to exist other blood fat reducing active component, and as lecithin etc., the effect for reducing blood fat that shows Monas cuspurpureus Went may be the collaborative result of multicomponent.
2, blood pressure lowering
Monas cuspurpureus Went is influential to hypertension model rat systolic pressure, can reduce the blood pressure of spontaneous hypertension rat (SHR), DOCA-salt type Hypertensive Rats (DHR), but the hypotensive activity to kidney vascular type Hypertensive Rats (RHR) is not obvious, wherein, the hypotensive activity of DHR is better than SHR.DHR is a low renin pattern type, and the prompting Monas cuspurpureus Went has hypotensive activity preferably to the low renin hypertension patient.
The present invention compared with prior art has the following advantages or good effect:
1, generally acknowledge that at present the blood fat reducing active component is a lovastatin in the Monas cuspurpureus Went, more, more deep to this composition Study;
2, Recent study finds to also have other component for reducing blood fat---lecithin in the Monas cuspurpureus Went, and the composition that improves the cardio-cerebrovascular function---daidzein;
Studies show that 3, that Monas cuspurpureus Went effect for reducing blood fat and control cardiovascular and cerebrovascular disease composition and mechanism complexity are not only that single component works, but act on body by multipath; In order to develop the function of Monas cuspurpureus Went blood fat reducing and control cardiovascular and cerebrovascular disease as far as possible all sidedly, clear and definite in Patent right requirement of the present invention: Monas cuspurpureus Went and extract thereof, effective site and effective ingredient (comprise lovastatin, lecithin, daidzein etc. and the Monas cuspurpureus Went discovered from now in to have a blood fat reducing active or improve the composition of cardio-cerebrovascular function) all can be used as raw material.
5, one of main purpose of patent of the present invention be by extensively, in depth study in Radix Notoginseng, the Monas cuspurpureus Went blood fat reducing and the control cardiovascular and cerebrovascular disease composition, be intended to find the compositions of Radix Notoginseng or Radix Notoginseng extract and Monas cuspurpureus Went or Monas cuspurpureus Went extract, wherein each composition has significant synergism, but not simply add and.
Embodiment 1:
Radix Notoginseng powder (100 order) and Hongqu powder (red colouring agent) (100 order) are in 1: 1 ratio, mix homogeneously.Transfer blood fat, transfer blood pressure, transfer tests such as blood glucose and atherosclerosis.
Embodiment 2:
Radix Notoginseng powder (100 order) and Hongqu powder (red colouring agent) (100 order) are in 1: 2 ratio, mix homogeneously.Transfer blood fat, transfer blood pressure, transfer tests such as blood glucose and atherosclerosis.
Embodiment 3:
Radix Notoginseng powder (100 order) and Hongqu powder (red colouring agent) (100 order) are in 2: 1 ratios, mix homogeneously.Transfer blood fat, transfer blood pressure, transfer tests such as blood glucose and atherosclerosis.
Embodiment 4:
Radix Notoginseng powder (40 order) is with 95% alcohol reflux three times, and the time is respectively 2h, 1h, 1h, merges three times filtrate, reclaims ethanol, extractum, drying for standby.
Hongqu powder (red colouring agent) (40 order) is with 95% alcohol reflux three times, and the time is respectively 2h, 1h, 1h, merges three times filtrate, reclaims ethanol, extractum, drying for standby.
Dry extract is 1. with 2. in 1: 1 ratio, mix homogeneously.Transfer blood fat, transfer blood pressure, transfer tests such as blood glucose and atherosclerosis.
Embodiment 5:
Radix Notoginseng total arasaponins (100 order) and Hongqu powder (red colouring agent) (100 order) are in 1: 10 ratio, mix homogeneously.Transfer blood fat, transfer blood pressure, transfer tests such as blood glucose and atherosclerosis.
Above embodiment is only for the invention will be further described, and the present invention is not subjected to the limitation of embodiment.
Experimental example 1: blood lipid regulation effect research
Test method:
The foundation of 1 rat obesity, hyperlipidemia model: wean male rat, average weight 110g, feed are made high fat high cholesterol diet 47d by oneself, and body weight gain and TC are all apparently higher than negative control group (P＜0.01), and model is successful.
2 lowering blood-fat and reducing weights test: by body weight and TC value the high-fat adiposity rat is divided into 2 groups at random, is high-fat adiposity matched group (O group), is tried the thing group, 10 of every group of rats, negative control group (O
1Group) continues to keep.Tried thing group feed and add and tried object height fat high cholesterol diet, the simple high fat high cholesterol diet of O group feed, O
1The common rat pellet of group feed is fed time 30d.
Blood Lipid such as following table: (mg/100dl)
Group Mus number (only) TC TG HDL-C
O
1 5 47.3±5.0 47.1±18.± 28.2±6.4
O 10 98.4±21.± 233.2±88.1 19.6±2.0
Tried thing 10 81.3 ± 13.9
149.8 ± 21.8
21.6 ± 4.5
: P＜0.01: P＜0.05 (comparing) with the O group
Conclusion
1, result of the test shows, being tried thing (patent compositions of the present invention) group compares with high-fat adiposity matched group (O group), reduce serum total cholesterol (TC) difference utmost point significance meaning is arranged, reduce serum triglycerides (TG) difference the significance meaning is arranged, and high density lipoprotein increasing-cholesterol (HDL-C) difference does not have the significance meaning, illustrates that said composition has the effect that reduces TC and TG preferably.
2, be 0.6g according to result of the test conversion people taking dose every day, further converting the people, to take lovastatin dosage every day be 4.5mg (is 1.5% to calculate by lovastatin content in the Monas cuspurpureus Went).
3, according to Beijing University's dimension letter XUEZHIKANG JIAONANG (product batch number: 20011209) every of defined contains lovastatin and must not be less than 2.5mg, one time 2, calculate for 2 times on the one, the people takes lovastatin dosage every day and is at least 10.0mg.
4, the people takes lovastatin dosage every day, and XUEZHIKANG JIAONANG approximately is 2 times of patent compositions of the present invention, this shows, each composition has synergism really in the said composition, and we also will carry out deep drug efficacy study to its synergy.
Claims (3)
1, the compositions of a kind of prevention or treatment cardiovascular and cerebrovascular disease is a raw material with Radix Notoginseng and Monas cuspurpureus Went, it is characterized in that in dry matter weight, with Radix Notoginseng powder and Hongqu powder (red colouring agent) by the weight proportion between 1: 2 to 2: 1 mixed described compositions.
2, compositions as claimed in claim 1 is characterized in that: the fungus that produces Monas cuspurpureus Went can be monascus (Monacus anka), Mauve aspergillar (Monacus Purpureus), monascus (Monacus albidus) turns white, Bark monascus (Monacus barkeri), smoky gray monascus (Monacus fulignosus), red monascus (Monacus rubervam), rust monascus (Monacus rubiginosus), in monascus (Monacusserorubescens) and the Mucor shape monascus (Monacus mucoroides) any reddens.
3, by the application of the described compositions of claim 1, it is characterized in that: said composition can be applicable to health food or food additive.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021137978A CN1183935C (en) | 2002-05-27 | 2002-05-27 | Notoginseng and fermented red rice composition for preventing and treating cardiac and cerebral vascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021137978A CN1183935C (en) | 2002-05-27 | 2002-05-27 | Notoginseng and fermented red rice composition for preventing and treating cardiac and cerebral vascular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1383871A CN1383871A (en) | 2002-12-11 |
| CN1183935C true CN1183935C (en) | 2005-01-12 |
Family
ID=4742812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021137978A Expired - Lifetime CN1183935C (en) | 2002-05-27 | 2002-05-27 | Notoginseng and fermented red rice composition for preventing and treating cardiac and cerebral vascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1183935C (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1919214B (en) * | 2005-08-24 | 2010-05-05 | 成都地奥九泓制药厂 | Monascus soft capsule and its preparation method |
| CN103251042A (en) * | 2012-03-08 | 2013-08-21 | 山东德圣医药科技有限公司 | Auxiliary hypolipidemic health-care food |
| CN102599501B (en) * | 2012-03-15 | 2013-11-06 | 宋靖钢 | Healthcare Hongyang capsule or tablet product for lowering lipid and protecting liver |
| CN103655697A (en) * | 2012-09-26 | 2014-03-26 | 郑州御寿堂健康产业科技发展有限公司 | Product for reducing blood fat and preparation process thereof |
| CN103493681A (en) * | 2013-09-24 | 2014-01-08 | 成都信息工程学院 | Method for producing medical mycoplasm by using pseudo-ginseng dregs in co-fermentation mode |
| CN104997823A (en) * | 2014-04-25 | 2015-10-28 | 北京北大维信生物科技有限公司 | Medicinal composition containing Folium Ginkgo, red yeast rice and panax notoginseng, and preparation thereof |
| CN105641509A (en) * | 2016-01-14 | 2016-06-08 | 吕海峰 | Traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular disease and application |
-
2002
- 2002-05-27 CN CNB021137978A patent/CN1183935C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1383871A (en) | 2002-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100336517C (en) | Red rice and gingko leaf composition for preventing and treating cardiovascular and cerebrovascular disease and its application | |
| CN1259935C (en) | Medicine for treating hyperlipemia | |
| CN104667283B (en) | A kind of compound medicine combination for treating dyslipidemia and atherosclerosis | |
| CN1183935C (en) | Notoginseng and fermented red rice composition for preventing and treating cardiac and cerebral vascular diseases | |
| EP2938350B1 (en) | Medical formulation for treating hypercholesterolemia | |
| CN1173707C (en) | Medicinal composition containing baicalin and caffoeoylchinic acid | |
| CN101961492A (en) | Ezetimibe compound preparation for treating dyslipidemia | |
| CN1213747C (en) | Specific therapeutic composition for treating AIDS | |
| CN105641509A (en) | Traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular disease and application | |
| CN105943583B (en) | Sweet wormwood herb and red yeast rice composition and application thereof | |
| Barylski | Monakolina i atorwastatyna w prewencji zdarzeń sercowo-naczyniowych-próba pozycjonowania | |
| CN101062097A (en) | Compound for improving and treating fatty liver disease | |
| CN101032534A (en) | Method of preparing jiubiying total saponins and the application thereof | |
| CN1660352A (en) | Combination of medication of possessing synergetic effect | |
| KR100532556B1 (en) | Composition for treating obesity and constipation containing extract of pine needle, green tea and black tea as an active ingredient | |
| CN1195537C (en) | External-applied Chinese medicine for treating hypertension and its preparing process | |
| CN102283831B (en) | Western medicine compound for curing coronary diseases and application | |
| CN1293914C (en) | Health care medicinal composition for improving sleeping and preparation preocess thereof | |
| CN1461656A (en) | Medicinal excipient-potassium alginate and its composition | |
| CN101053598A (en) | Medicinal composition for treating cardio-cerebralvascular diseases and diabetes | |
| CN112999216B (en) | A pharmaceutical composition containing tylosin for treating diabetic cardiomyopathy | |
| CN102161619B (en) | Ferulic acid Jiangtang compound salt as well as preparation method and application thereof | |
| CN101856403B (en) | Medicinal composition, preparation method thereof and pharmaceutical application | |
| CN1762440A (en) | Medicine for preventing and treating cardiovascular and cerebrovascular diseases | |
| CN104434920B (en) | A kind of pharmaceutical composition treating heart failure and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING YUNDA PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: YUNDA SCIENCE +. TECHNOLOGY CO., LTD. Effective date: 20071026 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20071026 Address after: 100021 Beijing city Chaoyang District East sanhuan Road No. 21 Yijingjiayuan No. 1 building 10 room G Patentee after: Beijing Yunda Pharmaceutical Co. Ltd. Address before: 650106 No. 59, medical Road, hi tech Industrial Development Zone, Yunnan, Kunming Patentee before: Yunda Science &. Technology Co., Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: MENG QINGFA Free format text: FORMER OWNER: BEIJING YUEDA PHARMACEUTICAL CO., LTD. Effective date: 20141209 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100021 CHAOYANG, BEIJING TO: 518100 SHENZHEN, GUANGDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141209 Address after: 518100 Dragon Pavilion 12E, dragon pearl garden, Buji Town, Longgang District, Guangdong, Shenzhen Patentee after: Meng Qingfa Address before: 100021 Beijing city Chaoyang District East sanhuan Road No. 21 Yijingjiayuan No. 1 building 10 room G Patentee before: Beijing Yunda Pharmaceutical Co. Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20050112 |
|
| CX01 | Expiry of patent term |